McKesson Corporation (MCK) fair value analysis

S&P 500 · Updated 2026-09-07

McKesson Corporation is a healthcare company that distributes pharmaceuticals, medical supplies, and healthcare information technology solutions to pharmacies, hospitals, and healthcare providers. The company operates primarily in the United States and also maintains operations in international markets including Europe, Canada, and other regions.

Forward Fair Value verdict

Fairly valued

Based on TickrTrends' weekly Forward Fair Value model, MCK is trading at within about 10% of estimated fair value.

MCK currently ranks #80 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Fairly valued for 3 consecutive weekly runs.

Last price: $907.99
Sector: Healthcare
12-month range: $734.82–$990.95

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: F
Leverage: Low
Margin trend: Stable
Revenue growth: Strong
RSI zone: Neutral
52-week position: The upper-middle quarter of its range
DCF cross-check: Undervalued

What our data shows for MCK

Our model validated 17 trailing price-to-earnings windows for MCK, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $734.82–$990.95.
The 14-day relative strength index sits at a neutral 55.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for MCK
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent MCK news

TickrTrends' derived news-sentiment signal for MCK is currently leaning positive, computed from recent coverage.

McKesson Corporation (MCK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript (seekingalpha.com, 2026-09-08)
McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates (finance.yahoo.com, 2026-09-08)
TickrTrends take: McKesson's pursuit of a 2,250,000,000 dollar precision medicine acquisition reflects its strategic push into higher-margin oncology services, an area where the Healthcare sector has seen sustained demand growth. Given TickrTrends' current Fairly valued assessment, investors monitoring the company should track how this deal impacts earnings accretion and whether it justifies valuation multiples in coming quarters. The capital deployment in precision medicine represents a shift toward specialized services that could alter the company's growth trajectory and profitability profile relative to its current valuation standing.
McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy (finance.yahoo.com, 2026-09-06)
TickrTrends take: McKesson's 2 billion dollar investment in oncology and precision medicine represents a significant capital deployment that reflects management's strategic priorities in a high-growth therapeutic area. Given TickrTrends' fairly valued assessment, investors should monitor how effectively the company deploys this capital and whether the acquisition generates returns that justify the spending relative to the company's current valuation multiple. The healthcare sector move positions McKesson to capture growth in oncology services, but the valuation impact will depend on the timing of revenue contribution and margin accretion from the acquired assets.

What people are saying

Follow the MCK conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — MCK's momentum indicator declined this week, shifting from a B rating to no rating, suggesting a loss of upward price movement. The stock remains in the Healthcare sector and maintains a fairly valued assessment based on current valuation metrics. This change in momentum may warrant attention from investors monitoring the company's near-term price trends.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is MCK stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), MCK is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.

What is MCK's TickrTrends verdict?

MCK's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.

How does MCK compare to other Healthcare stocks?

MCK ranks #80 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is MCK overbought or oversold?

MCK's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

MCK vs ABBV · MCK vs ACHC · MCK vs BVS · MCK vs COR · MCK vs HCSG